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Background: Antidepressants are commonly used to treat symptoms of anxiety and 
depression in inflammatory bowel disease (IBD). Recent studies suggest a link between IBD 
activity and an individual’s emotional state which raises the possibility that antidepressants 
may potentially modify the disease course of IBD. This systematic review thus primarily 
aims to evaluate the efficacy of antidepressants on IBD activity, and secondarily, on anxiety 
and depression.  
Methods: MEDLINE, EMBASE, Cochrane (IBD Group), CINAHL, AMED, PsycINFO and 
Open Grey were searched from 1990 onwards with no restrictions on study design. A quality 
appraisal was conducted using several scales as appropriate for each study design. A 
narrative synthesis was also conducted. 
Results: Fifteen eligible studies included in the review (1 RCT, 2 cohorts, 1 case-control, 1 
cross-sectional survey, 1 qualitative, 2 audits, 1 case-series and 6 case reports) examined a 
range of antidepressants. Twelve studies suggested antidepressants have a positive impact on 
IBD course. Nine studies reported anxiety and depression as an outcome, of these eight 
reported beneficial effects of antidepressants. Most of the studies were deemed to be at low 
risk of bias, apart from the case reports, which were at high risk of bias. 
Conclusions: The current research indicates antidepressants may have a beneficial effect on 
IBD course. However, it is currently not possible to determine their efficacy for certain due 
the lack of randomised trials. Further trials using objective measures of IBD activity, longer 
follow-up periods and larger sample sizes are needed. 
 
Key words: antidepressants; anxiety; depression; inflammatory bowel disease; systematic 
review  
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Introduction 
Depression and anxiety have a negative effect on disease course in inflammatory bowel 
disease (IBD). A recent systematic review of 86 studies found that adults with IBD are more 
likely to develop anxiety and depression prior to IBD onset, and rates of anxiety and 
depression are higher in IBD patients than the general population, and higher in those with 
active IBD compared to inactive (66.4% vs. 28.2% respectively for anxiety, and 34.7% vs 
19.9% for depression1). 
 
Antidepressants are often used to treat the anxiety and depression that is commonly 
experienced by patients with IBD, a case-note audit found 28.9% of IBD patients in a public 
tertiary hospital had used antidepressants at some point in their life2. Antidepressants have 
also been shown to be effective in treating gastro-intestinal (GI) symptoms associated with 
some other disorders. A systematic review and meta-analysis looking at the effect of 
antidepressants and psychological therapies on irritable bowel syndrome (IBS), a functional 
GI disorder, found antidepressants to have efficacy over placebo in the improvement of 
somatic bowel symptoms (relative risk 0.67; 95% CI 0.58,0.77) with similar effects observed 
for both selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs)3. 
A systematic review of animal models of colitis has found that desipramine and fluoxetine 
reduce the risk of colitis and improve inflammatory markers, with little evidence of adverse 
effects4.  
 
A previous systematic review published 10 years ago examined the effect of antidepressants 
in the treatment of IBD and found 12 publications, none of which were randomized 
controlled trials (RCTs)5. The review suggested that 16/20 patients experienced beneficial 
effects on physical IBD symptoms as a result of antidepressants but conclusions were limited 
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due to the observational nature of the research and very small samples of patients.  
 
Given psychological factors play an important role in IBD activity and antidepressants have 
been reported to have anti-inflammatory properties6, 7; antidepressants have the potential to 
be an adjuvant treatment for IBD. Despite the lack of conclusive evidence on efficacy or 
effectiveness, antidepressants are already prescribed in the treatment of somatic IBD 
symptoms2 and thus it is timely to review the role they may play in IBD management.  
 
The aim of this study is to 1) examine the evidence on the impact of antidepressants on 
disease activity, and 2) their impact on co-morbid symptoms of anxiety and depression in 
IBD. 
 
Materials and methods 
Search Strategy  
We searched MEDLINE, EMBASE, Cochrane (Cochrane inflammatory bowel disease and 
functional bowel disease group), CINAHL, AMED and PsycINFO. Search strategies were 
compiled with the assistance of an academic librarian. Papers published before 1990 were not 
included. No restrictions were placed on language during the searches although for practical 
reasons it was only possible to include English language papers. An example search strategy 
is presented in the Appendix. Searches were conducted on 3rd June 2016 by one author 
(BJDM).  
 
The reference lists of included articles were scanned and one journal (Gastroenterology) hand 
searched. Titles and abstracts of retrieved studies were screened for inclusion. The full text of 
potentially relevant articles was obtained and the inclusion and exclusion criteria were 
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applied.  
 
Inclusion Criteria 
Studies were included if they met the following criteria:  
• Contained human participants, clinically diagnosed with any form of IBD (i.e. 
Crohn’s Disease, Ulcerative Colitis or Intermediate Colitis based on clinical, 
histological, radiological or endoscopic criteria). 
• Participants could be any age and any sex. 
• Participants were prescribed or took any of the following antidepressants: tricyclics, 
MAOIs, SSRIs, SNRIs or atypical antidepressants. Antidepressants could be used 
both with and without other treatments, apart from other pharmacological psychiatric 
treatments (such as anxiolytics). Standard care was assumed. 
• Any comparator. 
• Any study design. 
• Contained an outcome measure of remission or anxiety /depression outcome (see 
Outcome Measures below) 
 
Exclusion criteria 
 Participants were prescribed or took any other form of medication used to treat 
depression or anxiety; such as herbal medicines and anxiolytics alone  
 
Outcome Measures  
For studies to be included in the review they had to include at least one of the following 
primary or secondary outcomes:  
 Primary Outcome 
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 Remission measured through changes in disease activity indices (DAI) as per 
respective cut-off values, as defined by study authors (e.g. Crohn’s Disease Activity 
Index (CDAI), Simple Clinical Colitis Activity Index (SCCAI)), using calprotectin, 
colonoscopy or other similar measures (e.g. blood).  
 Secondary Outcomes 
 Anxiety and depression symptoms, as measured through using any relevant diagnostic 
interview technique or screening scale.  
 
Data Extraction 
Data pertaining to the sample, methods, and results were extracted from each the included 
studies by one author (BJDM).   
 
Quality Assessment 
Other than human participants the present review applied no restrictions on study design, 
therefore the variety of study designs necessitated the use of several different quality 
assessment tools. The Cochrane Risk of Bias tool was used for randomised trials8, this was 
based on eight questions which can addressed with either ‘Low risk’ or ‘High risk’. The 
Newcastle-Ottawa Scale (NOS) for observational studies (case-control and cohorts)9, for 
which a study can score a possible of eight points, a higher score signifies a lower risk. The 
National Institute of Health (NIH) quality assessment tool for audits, case reports and case 
series10. Another NIH quality assessment tool was used to assess the quality of cross-
sectional surveys11. Both of the NIH tools used gave a final quality rating of ‘Good’, ‘Fair’ or 
‘Poor’. Qualitative studies were assessed using the Critical Appraisal Skills Programme 
(CASP) tool 12. The CASP tool has 10 questions which can be answered ‘Yes’, ‘Can’t tell’ or 
‘No’; a ‘Yes’ would imply a low risk of bias. 
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Data Analysis 
A narrative synthesis was used to describe and compare the studies. A meta-analysis was 
planned but not carried out due to heterogeneity of study design and outcomes. 
 
Results 
A total of 2,193 studies were retrieved with 1,840 screened after duplicates were removed 
(Figure 1). Fifteen studies were included in the review: one placebo-controlled RCT, one 
prospective and one retrospective cohort study, one retrospective case-control study, one 
cross-sectional survey, one qualitative study, one report on a clinical case note audit, one 
audit and six case reports. The follow-up period of the studies varied from 6 weeks to 11 
years. The majority of the studies were from the United States (n=8) and Australia (n=3), 
with one study each from England, Iran, New Zealand and India.  
 
Quality Assessment 
Quality assessments of each individual study can be found in Tables 1-4. The RCT 13 was at 
low risk of bias with only high-risk scores from the sections assessing attrition bias.  
 
Using the NOS for non-randomised studies, Yanartas et al. (2016) was at low risk of bias, 
and Iskandar et al. (2014) was at mid-to-high risk of bias, the primarily because it contained 
an IBS comparative cohort which was irrelevant for this review. The case control study14 was 
deemed to be low risk of bias. The main weakness of this study was the representativeness of 
the participants because they were sampled from a single tertiary care IBD centre in London. 
In the cross-sectional survey15 six out of the seven relevant categories received a ‘Yes’ on the 
NIH tool. The reasons for not receiving a ‘Yes’ on the other category was because it was not 
possible to determine if 50% of eligible persons took part in the study. The study was given 
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an overall quality rating of ‘Good’ indicating a low risk of bias. The single qualitative study16 
met all the nine criteria as set out by the CASP assessment tool and the study was deemed to 
be at low risk of bias.  
 
The NIH tool was used to quality assess the two audits, the case series and the six case 
reports.  The report on a case note audit2, met all of the criteria apart from length of follow-
up, as this was not applicable; scoring ‘Good’ overall deeming it at low risk of bias. The 
other audit17 was deemed at high risk of bias, only receiving a ‘Yes’ in three of the nine 
categories.  
 
The case-series18 was at low risk of bias only being marked down because the length of 
follow-up was inadequate. Of the case reports the study quality was generally poor, so a high 
risk of bias. A weakness of all the case reports, of which two were abstracts, is that the 
outcome measures were not clearly defined, with often incompletely reported results. 
 
Narrative synthesis 
Of the 15 included studies, 14 (93%) addressed the primary outcome measure of remission 
and 10 (67%) addressed the secondary outcomes of anxiety/depression. See Table 5 for a 
description of each study and Table 6 for results.  
 
RCT 
The RCT was conducted between 2013-2014 in Iran13. Forty-four participants were randomly 
allocated to be either prescribed duloxetine (60mg once a day) or a placebo for 12 weeks. 
Anxiety and depression was measured using the Hospital Anxiety and Depression Scale 
(HADS) and symptom severity using Lichtiger Colitis Activity Index (LCAI). Five patients 
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were lost to follow-up in the intervention group and four in the control group, leaving a total 
of thirty-five participants (UC: 22; CD: 13) in the analysis. 
 
Symptom severity significantly improved in the intervention group compared to the control 
group (P = 0.02). Depression and anxiety also improved significantly in the intervention 
group compared to the control group (depression P = 0.041; anxiety P = 0.049). 
 
Cohorts 
The retrospective cohort study included 81 participants taking TCA (UC: 23; CD: 58)19 who 
were followed over 11 years using outpatient records from a Gastroenterology practice in St. 
Louis, Missouri. Baseline symptom severity was assessed on a 4-point Likert scale (0 = no 
symptoms to 3 = severe, disabling symptoms) with no significant difference between disease 
types. AD treatment responses were graded using an established 4-point scale (0=no 
improvement to 3=complete satisfaction). Patients with UC responded significantly better 
than patients with CD at first follow up (time frame not stated), mean 1.86 (SEM, standard 
error of the mean 0.13) for UC and 1.26 (0.11) for CD (P = 0.003). Eighty-three per cent of 
UC patients had at least a moderate symptomatic improvement on TCA, compared with 50% 
of CD patients (P = 0.01). At the second follow (time frame not stated) up there was no 
significant difference between the disease types (CD 1.31 (SEM 0.16); UC 1.47 (0.17), P = 
0.76) or on whether they had at least a further moderate symptom response, (CD 56%; UC 
40% P = 0.16). 
 
The prospective study20 followed 67 patients (UC: 36; CD: 31) from an IBD-specific 
Gastroenterology outpatient clinic at a hospital in Istanbul, between June 2013 and June 
2014. The CDAI and Modified Mayo Score (MMS) were used to measure disease activity for 
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CD and UC, respectively, as well as C-reactive blood count. Anxiety and depression were 
assessed using HADS, Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).  
 
Antidepressant treatment was not associated with a significant improvement in CDAI 
compared to the control group (mean improvement -62.9 (SD 99.5), P = 0.57), nor was it 
associated with improvement in MMS (-1.6 (3.4), P = 0.926). However, a significant 
improvement was seen in anxiety and depression when compared to the control group, P = 
0.001 and P = 0.017, respectively.  
 
Case-control study 
The case-control study retrospectively compared 58 participants, 29 (UC: 14; CD: 15) who 
were sampled from an adult and paediatric IBD centre in London, UK14. In the intervention 
group (n = 29) antidepressants were used to treat mood disorders, the matched controls (n = 
29) received no antidepressants therapy; patients were matched based on age, sex, disease 
type, medication at baseline, and relapse rate in year 1. Patients were assessed the year before 
and the year after initiation of antidepressant therapy.  
 
Outcomes included number of relapses, number of endoscopic procedures, number of 
outpatient attendances and hospital admissions and number of courses of steroids. Fewer 
relapses and courses of steroids in the year after starting an antidepressant were experienced 
in the intervention group than in the year before (1 [0–4] (median [range]) vs. 0 [0–4], P = 
0.002; 1 [0–3] vs. 0 [0–4], P < 0.001, respectively). The controls showed no changes between 
years 1 and 2 in relapses (1 [0–4] vs. 1 [0–3], respectively) or courses of steroids (1 [0–2] vs. 
0 [0–3]). There was a significant difference between the two groups for number of relapses 
(P = 0.03), but not for course of steroids (P = 0.07). 
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Cross-sectional Survey 
The cross-sectional online survey, advertised between March 2012 and April 2013, included 
98 participants (UC: 32; CD: 48; IC: 3) from a non-clinical population recruited via 
Australian IBD advocacy and support group15.  Participants were required to be taking 
antidepressants or had previously been on antidepressants since their IBD diagnosis. The aim 
of the study was to explore the use and type of antidepressants currently prescribed to IBD 
suffers, their effects on symptoms and experiences of them. 
 
Participants had been taking antidepressants for an average of 4 (SD 3.9) years, with a range 
of 4 weeks to 15 years. Of those individuals taking antidepressants 79% reported perceived 
improvements, however, 67% had observed no change in perceived disease activity. Disease 
activity was found to improve in 25% of participants. The study also showed perceived 
psychological well-being had improved in 87% of participants.  
 
Qualitative study 
The qualitative study interviewed 15 participants taking antidepressants, sampled from The 
Royal Adelaide Hospital, a tertiary teaching hospital in South Australia16. The interviews, 
conducted between January and March 2011, were semi-structured, containing open-ended 
questions relating to IBD history, reasons for antidepressant therapy and details of the 
therapy, acceptance of the treatment, side effects, impact on IBD and quality of life, and 
attitudes towards taking part in future trials.   
 
The study showed that antidepressants helped disease course (n = 5), reduced pain and 
frequency of bowel movements (n = 3) and reduced the frequency of symptoms or flare up (n 
= 3). Conversely, n = 10 reported that antidepressants did not influence disease course, 
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although the authors did concede that it was difficult to distinguish between the effectiveness 
of different treatments. The study also showed that the majority of the participants had a 
positive attitude towards antidepressants (n = 9). Twelve of the participants stated they would 
take part in further trials; two didn’t want to change their antidepressant treatment due to their 
success with it. 
 
Audits 
The case-note audit was conducted at the centre where the participants from the qualitative 
study, mentioned above, were sampled. This retrospective analysis was from an IBD database 
at an Australian tertiary hospital, and assessed participants for type, frequency and impact of 
antidepressant therapy on IBD course2.  
 
The audit showed that from 287 participants (UC: 95; CD: 179; IC: 13) 51 (18%) were 
currently taking antidepressants. Within the 51 taking antidepressants, 15 (30%) individuals 
had inactive disease but presented with symptoms such as pain or diarrhoea, consistent with 
functional bowel disorders, 11 (22%) were in full remission with no disease activity, 2 
(0.01%) had active disease and the data for 23 (45%) participants was not recorded. Seventy-
one patients had a history of antidepressant use, 45 (63%) were prescribed for anxiety and 
depression, or both; ten (14%) were for somatic complaints and no data were available for the 
remaining 16 (22.5%) patients. While on antidepressants 19 (28%) had inactive disease but 
had functional symptoms, 12 (17%) had active disease and 9 (13%) had inactive disease.  
 
The other study (reported as an abstract)17 we have classified as an audit but may be better 
described as a series of annually conducted cross-sectional surveys of patient IBD activity 
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and antidepressant use in an IBD clinic. The results showed that in 855 IBD participants (UC: 
353; CD: 76) mean IBD activity decreased over four years, independent of SSRI use. 
 
Case-series 
The one case-series included18 studied 8 IBD participants from a Gastroenterology tertiary 
care centre in Seattle, attending from March to October 1993. Participants were screened and 
selected if they were diagnosed with major depression, using HAM-D. 
 
Participants were interviewed at baseline using National Institute of Mental Health (NIMH) 
Diagnostic Interview Schedule (DISC), a structured interview process used to determine 
current and lifetime diagnoses of a number of psychiatric disorders. Participants also had GI 
symptom interviews 
 
All participants were then treated with paroxetine and received follow-up interviews at 8 
weeks. Disease activity was not reported in the study. Depression improved significantly 
when comparing participant’s pre- and post- data, P = 0.0001 (pre-treatment 29.0 (SD 7.7); 
post-treatment 8.1 (6.1)). 
 
Case Reports  
Of the six included case reports18, 21-26, two were reported as abstracts only25, 26. One of the 
abstracts describes an individual with UC25, the rest of the studies refer to patients with CD. 
The UC patient had generalised anxiety disorder and was treated with mirtazapine (15mg) at 
night and after six weeks had relief from bloody diarrhoea, rectal pain and anxiety. The other 
abstract described a 64 year-old male with six months of 4-6 watery bowel movements per 
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day26. The patient was receiving mirtazapine and sertraline for severe depression, when the 
dosage was changed to be taken at night the patient had relief from IBD symptoms. 
 
One case report found phenelzine to reduce bowel movements from ten watery movements 
per day to one soft movement per day and without any cramping22. The participant was 
tapered off any other medications and the symptoms only returned when phenelzine was 
stopped after two years. Another report found no improvements on IBD course after 
treatment with transdermal amitriptyline, however no adverse effects were observed24. The 
two remaining studies reported CDAI; in both these studies all the patients (n = 6) achieved 
remission with antidepressant treatment18, 23. 
 
Discussion 
The majority of studies (80%) included in this systematic review reported antidepressants to 
have a beneficial effect on IBD course and 60% reported a beneficial effect on anxiety and 
depression levels. Despite this encouraging finding, due to the limitations of the 
observational study designs included, no firm conclusions can be drawn about the efficacy or 
effectiveness of antidepressants in IBD. Nevertheless, judging by the success of 
antidepressant treatment in functional gut disorders and particularly the improvements in 
bowel functions and abdominal pain3, 27, but also by a significant proportion of IBD patients 
actively using antidepressants (between 10-30%)2,28, 29, antidepressants have a role to play in 
IBD management. Whether this is because they influence the inflammatory processes or 
simply because they improve mood is hard to decipher at present and their role in IBD should 
be further investigated.  
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To the authors knowledge, only one other similar systematic review has been conducted5. 
The systematic review included 12 relevant articles, however, the authors found a paucity of 
high quality data. None of the included articles were RCTs, five of them were not primary 
research and the same group conducted seven of the studies. The previous review, whilst 
acknowledging the poor methodological quality of the included studies, concluded that the 
results suggest antidepressants have the potential to be used to help certain individuals cope 
with the emotional comorbidities of IBD; such as anxiety and depression, improve quality of 
life and possibly have a beneficial effect on the IBD course. In the 10 years since this review 
was conducted the evidence appears to have improved slightly. One RCT was included in the 
present review but it had some limitations which may have biased the results. It should be 
noted another small trial has been published in recent weeks30, reporting no impact of 
fluoxetine on disease activity over 12 months in CD but observing some potentially positive 
impact of this antidepressant on the cytokine profiles.  
 
There is much speculation around the potential mechanism of action of antidepressants in 
altering the course of IBD. Three of the included studies13, 14, 20 hypothesised that the 
improvements seen in patients could be because of the anti-inflammatory properties observed 
in antidepressants31. There is evidence that antidepressants can lower circulating levels of 
tumour necrosis factor-alpha (TNF) and so could potentially provide the reason for the 
positive effects of antidepressants on IBD course32, 33. Alternatively, and most probably, 
improvements seen can be a direct result of the reduction in the symptoms of anxiety and 
depression as a result of antidepressants. The current brain-gut-microbiome research 
reviewed elsewhere points towards this explanation34-36. However, further research is 
required to conclusively determine the exact mechanism or mechanisms of action. 
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Current Guidelines  
A recent review of the international evidence-based guidelines on managing IBD and its 
comorbid psychosocial issues37 concluded that psychological distress should be screened for 
and treated appropriately, with psychotherapy / psychopharmacotherapy offered if required. 
The dominance of observational studies in the present review precludes a judgement on the 
efficacy of antidepressants on IBD course, but results indicate the possibility of an effect 
which needs experimental verification. 
 
Limitations of Included Studies  
The majority of the included studies were observational, uncontrolled and non-randomised. 
Only three studies had follow-up periods at two years or more, five studies had follow-up 
periods of 12 weeks or less. IBD often takes longer than 12 months to go through cycles of 
relapse and remission. Population-based studies have shown that after five years of being 
diagnosed as in remission, nearly 100% of patients have relapsed38, therefore follow-up 
periods that are shorter than this are not likely to capture long term effectiveness.  
Many of the studies had small sample sizes and only sampled participants from a single 
source; therefore, participants are unlikely to be representative of the IBD population as a 
whole. For example, in the case-control study14 participants were sampled solely from a 
national IBD patient advocacy group. Furthermore, all studies did not account for differences 
by sex in their analyses, which is important because  women may be at greater risk of anxiety 
and depression than men39. 
 
The final limitation of the included studies is the study designs. Only one RCT was included 
and six (40%) were case reports two of which were incompletely reported conference 
abstracts.  
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Strengths and Limitations of the Present Review 
There were a number of strengths to the present review, the first being its comprehensive 
literature search which included an extensive search string and a large number of databases, 
including grey literature. The review was also adapted to account for the differing study 
designs by using a range of quality assessment tools.  
 
Despite these strengths there were a number of limitations to the review. Due to limited 
resources it was not possible to have a second reviewer at either the screening or data 
extraction stages of the review. The review was also limited by only including articles 
published in English. However, only 30 non-English publications were excluded and based 
on the percentage of relevant English papers once titles and abstracts were screened (2.9%), it 
would be unlikely that the non-English language publications would have yielded further 
studies. 
 
Future research 
Further randomised controlled trials are required to improve understanding of the impact of 
antidepressants on IBD course. Trials should aim to recruit larger numbers of participants and 
analyses should take account of potential sex differences. Future trials should also prioritise 
objective measures of disease activity (i.e. calprotectin, colonoscopy) over subjective (i.e. 
disease activity indices) when assessing IBD activity.  
 
The previous systematic review5 recommended future research should differentiate between 
CD and UC, this recommendation has not changed in light of the present reviews findings. 
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Finally, longer follow up periods (at least five years) are required to more accurately 
determine the efficacy of antidepressants therapy on disease course.  
 
Conclusion 
Antidepressants are commonly used by IBD patients, however, based on the findings from 
this systematic review, it is not possible to determine for certain whether antidepressants have 
a beneficial effect on the course of IBD. The state of research has improved over the last 10 
years however nearly all the evidence comes from observational studies where cause and 
effect are difficult to attribute.  Further properly conducted RCTs with validated measures, 
larger samples and adequate follow-up periods are required to accurately determine the 
efficacy of antidepressants on improving disease course. 
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Use of antidepressants 
not evaluated (n=4) 
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(n=5) 
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Table 1. Quality Assessment of Randomised Controlled Trial – Cochrane Risk of Bias Tool 
 
 
Random 
sequence 
generation 
(selection 
bias) 
Allocation 
concealment 
(selection 
bias) 
Blinding of 
participants 
and personnel 
(performance 
bias) 
Blinding of 
outcome 
assessment 
(detection bias) 
(patient-
reported 
outcomes) 
Blinding of 
outcome 
assessment 
(detection 
bias)  
Incomplete 
outcome data 
addressed 
(attrition bias) 
(Short-term 
outcomes  (2-
6 weeks)) 
Incomplete 
outcome data 
addressed 
(attrition bias) 
(Longer-term 
outcomes  (>6 
weeks)) 
Selective 
reporting 
(reporting 
bias) 
Daghaghzadeh 
(2015) 
Low Risk Low Risk Low Risk Low Risk Low Risk High Risk High Risk Low Risk 
 
Table 2. Quality Assessment of Cohort Studies & Case Control Study – Newcastle-Ottawa Scale 
Cohort studies Represent-
ativeness 
of exposed 
cohort (/1) 
Selection of the 
non-exposed 
cohort (/1) 
Cohort 
Study 
Selection Comparability Outcome Was follow-
up long 
enough for 
outcomes to 
occur? (/1) 
Adequacy 
of follow-
up of 
cohorts 
(/1) 
Total 
(/8) 
Yanartas (2016) * * * * * * * * 8 
Iskandar (2014) * - * - - * * * 5 
Case Control 
Study 
Is the case 
definition 
adequate? 
(/1) 
Representativeness 
of the cases (/1) 
Selection 
of controls 
(/1) 
Definition 
of controls 
(/1) 
Comparability of 
cases and 
controls on the 
basis of the 
design or 
analysis (/2) 
Assessment 
of exposure 
(/1) 
Same method 
of 
ascertainment 
for cases and 
controls (/1) 
Non-
Response 
Rate (/1) 
 
Goodhand 
(2012) 
* - * - ** * * * 6 
 
Table 3. Quality Assessment of Cross-sectional Survey, Audits, Case-series & Case Reports – National Institute of Health tool 
Cross 
Sectional 
Survey 
Objective 
stated 
Population 
specified 
& 
defined? 
Participation 
rate  ≥ 50% 
Uniform 
selection 
and 
recruitment 
Sample 
size / 
power 
estimate 
Exposure(s) 
measured 
prior to the 
outcome(s)  
Sufficient 
timeframe  
Exposure 
appropriately 
measured 
Exposure 
measures 
defined, 
valid, reliable 
&consistently 
implemented 
Exposure(s) 
assessed >  
once 
Outcome 
measures 
defined, 
valid, 
reliable & 
consistently 
implemented 
Outcome 
assessors 
blinded 
Attition ≤ 
20% 
Confounding 
variables 
measured 
and adjusted 
for 
Quality 
Rating 
(Good/ 
Fair/ 
Poor) 
Mikocka-
Walus 
(2014) 
Yes Yes CD Yes N/A N/A N/A Yes Yes N/A Yes N/A N/A N/A Good 
Audits, 
Case-
series & 
Case 
Report 
Question 
/ 
objective 
stated 
Population 
specified 
& defined  
Consecutive 
cases 
Subject comparability Intervention clearly described Outcome measures defined, valid, reliable & 
consistently implemented 
Sufficient 
length of 
follow-
up  
Statistical 
methods 
well 
described 
Results well 
described 
Quality 
Rating 
(Good/ 
Fair/ 
Poor) 
Mikocka-
Walus 
(2012a) 
Yes Yes Yes Yes Yes Yes N/A Yes Yes Good 
Ramos 
Rivers 
(2014) 
No No N/A Yes No No Yes Yes No Poor 
Walker 
(1996) 
Yes Yes Yes Yes Yes Yes No Yes Yes Good 
Kane 
(2003) 
Yes No No No Yes No Yes N/A No Poor 
Kast 
(1998) 
Yes Yes N/A N/A Yes No Yes NR Yes Poor 
Kast 
(2001) 
No Yes No No Yes No CD NR Yes Poor 
N/A – Not applicable; CD – Can’t determine. 
Table 4. Quality Assessment of Qualitative Study – Critical Appraisal Skills Programme tool 
 Was 
there a 
clear 
statement 
of the 
aims of 
the 
research? 
Is 
Qualitative 
method 
appropriate? 
Was the 
research 
design 
appropriate 
to address 
the aims of 
the 
research? 
Was the 
recruitment 
strategy 
appropriate 
to the aims 
of the 
research? 
Was the 
data 
collected 
in a way 
that 
addressed 
the 
research 
issue? 
Has a 
relationship 
between 
researcher 
and 
participant 
been 
adequately 
considered? 
Have ethical 
issues been 
taken into 
consideration? 
Was the 
data 
analysis 
sufficiently 
rigorous? 
Is there a 
clear 
statement 
of 
findings? 
How valuable 
is the research? 
Mikocka-
Walus 
(2012b) 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Showed 1/3 
patients to have 
perceived 
improvements. 
Informed future 
RCTs. 
 
Table 5. Summary table of the included studies  
Author 
(Year), 
Country 
Study 
Design 
Participants Study Details Disease 
Type 
Measurement & Assessment Follow 
Up IBD Depression & 
Anxiety 
Daghaghzadeh 
(2015), Iran 
Placebo-
controlled 
RCT 
35 participants between 18-
65 years old (Mean (SE) 
age: 38 (8.08)), with no 
flare up over previous 6 
months. Selected from the 
gastrointestinal clinic of 
Alzahra Hospital (Isfahan) 
between 2013 and 2014. 
 
Experimental group n=17 
(47% female) 
Control group n=18 (44% 
female) 
 
 
Two groups. Intervention group (n=17) took 
duloxetine 30-60mg once per day for 12 weeks. 
Control group (n=18) was placebo controlled, 
the subjects received placebo in the same form 
and packages as duloxetine for the same length 
of time. All participants also received 
mesalazine, 2-4mg daily. 
 
Randomisation: A third-party physician using 
tables of random numbers conducted the 
randomisation.  
 
Blinding: A psychologist who was not 
informed about grouping of the subjects 
assessed questionnaire scores. 
UC = 22 
CD = 13 
 
Disease duration, 
mean (SD): 
Intervention - 6.49 
(3.27) yrs; Control – 
8.17 (4.29) yrs 
(p=0.538). 
 
Symptom severity 
measured using 
Lichtiger Colitis 
Activity Index 
(LCAI). 
Depression and anxiety: 
Mean (SD) score across 
both groups: 9.22 (3.45) 
and 8.17 (4.29), 
respectively. Measured 
using HADS. 
12 
weeks 
Yanartas, O. 
(2016), New 
Zealand 
Prospective 
Cohort 
67 participants (43 (64%) 
female) above 17 years old, 
mean age was 40.71±12.71 
yrs, followed up in the IBD-
specific gastroenterology 
outpatient clinic at Marmara 
University Hospital 
between June 1, 2013, and 
June 1, 2014. 
 
 
 
Participants had psychiatric interviews using 
SCID-I. Participants also had SF-36 and 
Arizona Sexual Experience Scale (ASEX) tests 
for assessing QoL and sexual dysfunction.  
 
Assessments before and after 6 months; 47 
completed antidepressant therapy (group A), 20 
didn’t (group B). Most common antidepressants 
used were sertraline (21.0%) and escitalopram 
(15.8%). 
UC = 36  
CD = 31 
CDAI and MMS for 
the assessment of 
disease activity in 
patients with CD or 
UC, respectively. 
Along with CRP, 
complete blood count, 
and routine blood bio- 
chemistry were 
collected on all visits. 
Major depression 
(43.2%) and 
Generalised Anxiety 
Disorder (15%) using 
HADS. 
6 
months 
Iskandar, H., et 
al (2014), USA 
Retrospective 
Cohort 
81 participants with IBD. 
Mean (SD) age: 41.3±1.7; 
69.1% females 
 
 
Outpatient electronic medical records were 
reviewed to identify patients over an 11-year 
period between July 2000 and June 2011. 
 
TCA median dose (amitriptyline, nortriptyline, 
desipramine) 25mg, range 10-150mg. TCA 
dose increase by second follow up, 29/81 
(35.8%).  Currently taking biologics (22.4%), 
imunno-modulators (31.0%) and 5-ASA 
(12.1%). 
UC = 23 
CD = 58  
Baseline symptom 
severity was 
assessed on a 4-
point Likert scale 
(0=no symptoms, 
3=severe, disabling 
symptoms). AD 
treatment responses 
were graded using 
an established 4-
Data was self-reported. 
 
Depression, n=23 
(28.4%). Anxiety, n=5 
(6.2%).  
Both, n=10 (12.3%). 
11 
years 
 point scale (0=no 
improvement; 
3=complete 
satisfaction). 
 
 
Goodhand 
(2012), USA 
Retrospective 
Case-control  
58 participants divided 
equally into two groups 
(n=29). Seventeen females 
in each group. From a 
tertiary adult and paediatric 
IBD center located in 
London. 
 
Patients were already using 
Corticosteroids, 5-ASA, 
Immunosuppressive agents, 
anti-TNF. 
IBD patients using ADs to treat concomitant 
mood disorders. Citalopram 20mg (20-60mg) 
and fluoxetine 20mg (20-60mg) were the most 
commonly used ADs; other SSRIs were used 
and TCAs, NaSSa and SNRIs. 
 
Controls didn’t receive ADs and were matched 
based on gender, age at diagnosis 65 years, and 
disease duration 63 years were sought and then 
screened in detail to match for disease 
phenotype, baseline medications, surgeries, and 
relapse rate in year 1.  
 
 
UC =14 
CD = 15 
(in each 
group) 
Median age at 
diagnosis, yrs 
(range): AD group – 
26 (13-72); Controls 
– 29 (12-62).  
Median disease 
duration, yrs 
(range): AD group – 
5.2 (1-40); Controls 
– 4.2 (1-31). 
NR 2 years 
Mikocka-
Walus, A 
(2014), 
Australia 
Cross-
Sectional 
Survey 
98 participants (76 (78%) 
female) from a national IBD 
advocacy and support group 
accessed the survey. Mean 
(SD) age: 37.7 (11.9). 
 
Participants were currently 
taking a mixture of or solely 
conventional and alternative 
treatments. 
Questions in the survey were related to type and 
dosage of ADs; perceived outcome of the 
treatment; perspectives and experiences with 
the use of ADs as well as views on the 
interactions between AD treatment and their 
disease course; respondents' acceptability of 
trials with ADs. 
UC = 32  
CD = 48 
IC = 3 
Time with IBD 
symptoms, mean 
(SD): 13.7 (9.5) yrs. 
Time since IBD 
diagnosis, mean 
(SD): 9.2 (8.8). 
 
As diagnosed by a 
clinician.  
 
Depression (n=25) 
Anxiety (n=10) 
Both (12). 
 
 
N/A 
Mikocka-Walus 
(2012b), 
Australia 
Qualitative - 
Interview 
15 participants taking ADs 
(9 (60%) females) selected 
from a case-note audit. 
Mean (SD) age: 45.8 
(17.11) years.  
 
Most common symptoms: 
pain (86.7%), diarrhoea 
(66.7%), nausea (33.3%), 
fatigue 26.7%, bloating 
(26.7%), and difficulties 
tolerating medications 
(20.0%). 
Semi-structured interviews were conducted. 
 
Open-ended questions were asked about IBD 
history, reasons for taking ADs and details of 
this therapy (type, dose, length of treatment, 
etc.), acceptance of this treatment, patients’ 
observations in relation to side-effects and 
impact on IBD (e.g. impact on pain, frequency 
of bowel movement), observed impact on QoL, 
attitudes towards ADs, and attitudes towards 
future trials with the use of ADs. 
 
UC = 1  
CD = 12 
Colitis 
of 
undeter
mined 
aetiolog
y = 1 
Time since 
diagnosis ranged 
from 3 to 30.5 
years, mean (SD) 
16.8 (8.9). The 
number of current 
symptoms reported 
per patient ranged 
from 1 to 7, mean 
(SD) 3.5 (2.0). 
 
 
Self-reported data.  
 
Depression or depressed 
mood, reported by 10 
patients (66.7%), and 
anxiety or 
anxious mood, reported 
by seven patients 
(46.7%). 
 
N/A 
Mikocka-Walus 
(2012a), 
Australia 
Report on 
Clinical Case-
Note Audit 
287 (143 (50%) females). 
Mean (SD) age: 47 (17).  
 
Patients taking the 
following: 5-ASA, 
azathioprine, biologics, 
corticosteroids, 
metronidazole, salazopyrin, 
pain killers, 
benzodiazepines. 
 
Patients’ details were collected from an IBD 
database at an Australian tertiary hospital. 
 
Details on frequency, type and outcome of AD 
treatment in terms of IBD course were 
collected. 
UC = 95 
CD = 
179 
IC = 13 
(see table 2) As diagnosed by 
clinicians.  
 
Depression (45%) 
Combined depression and 
anxiety disorder (23.5%) 
N/A 
Ramos Rivers 
(2014), USA 
Audit 
(Abstract) 
855 IBD, mean age 47±15 
(422 (52%) females) 
Electronic medical records (EMR) were used to 
identify frequency and classes of AD use.  For 
the most frequently used ADs, differences in 
QoL (SIBDQ) and IBD activity between pts 
taking ADs and those who did not during that 
same 4 year period were evaluated. 
 
 
UC = 
353 
CD = 76  
History of GI 
surgery, 46.7% 
 
IBD activity 
measured using 
HBI/UCDAI   
N/A 4 years 
Walker (1996), 
USA 
Case-series 8 IBD participants, 18-years 
old or older. Selected from 
tertiary care medical faculty 
in Seattle. 
Patients interviewed using NIMH Diagnostic 
Interview Schedule (DIS), GI symptom 
interview and the Briere Child Maltreatment 
Interview (history of childhood abuse and 
neglect), SF-36, Tri-dimensional Personality 
Questionnaire. 
 
Patients treated with paroxetine, 20mg for first 
month. Second month 2 patients moved 40mg. 
At the end of follow-up patients re-interviewed, 
SF-36 and HAM-D. 
 
 
Not 
specifie
d 
GI symptom 
interview 
All participants diagnosed 
with major depression. 
Confirmed by Hamilton 
Depression Inventory 
(HAM-D) 
8 weeks 
Kane (2003), 
USA 
Case Report 4 participants (2 women, 2 
unspecified) 
Bupropion 100mg for depression or smoking 
cessation for at least 6 weeks. 
 
CD NR As diagnosed by a 
clinician.  
Depression (n=2) 
6 weeks 
Kast (1998), 
USA 
Case report 33-year-old female. 
 
Currently taking 75 mg 
azathioprine, 60 mg 
prednisone, and 3 
acetaminophen/oxycodone 
tablets daily. 
Phenelzine 15 mg three times daily for one 
month, then 30mg three times daily after for 2 
years. 
CD 18-year history of 
CD. Has undergone 
3 bowel resections 
and had 10 watery 
bowel movements 
with severe 
Major depressive episodes 
and anxiety, as diagnosed 
by a clinician.  
 
NR 
RCT – Randomised controlled trial; SE – Standard error; SD – Standard deviation; UC – Ulcerative colitis; CD – Crohn’s disease; IC – Intermediate colitis; LCAI – Litchtiger colitis activity index; 
HADS – Hospital anxiety and depression scale; IBD – Inflammatory bowel disease; ASEX – Arizona Sexual Experience Scale; QoL – Quality of life; CDAI – Crohn’s disease activity index; CRP – 
C-reactive protein; SCID-I – Structured clinical interview for DSM disorders; AD – Antidepressants; 5-ASA – 5-Aminosalicylic acid; TNF – Tumour necrosis factor –alpha; SSRI – Selective 
serotonin reuptake inhibitor; SNRI – Serotonin & Noradrenaline reuptake inhibitor; NaSSa - Noradrenergic and specific serotonergic antidepressants; SIBDQ - Short Inflammatory Bowel Disease 
Questionnaire; GI – Gastrointestinal; HBI – Harvey-Bradshaw Index; UCDAI – Ulcerative colitis disease activity index; HAM-D – Hamilton depression scale; SF-36 – Short form -36; DIS – 
Diagnostic interview schedule; NR – Not reported. 
abdominal cramping 
daily. 
Kast (2001), 
USA 
Case Report 44-year-old woman. Taking 
fluoxetine 40 mg every day 
for depression, and 
mesalamine 500 mg twice a 
day. 
 
45-year-old man.  
Bupropion 150mg three times daily for 
depression (female) and smoking cessation 
(male). 
CD Woman - 10-year 
history of IBD 
(CDAI – 202). 
 
Man - 20-year 
history of IBD with 
multiple surgeries, 
including 4 small 
bowel resections 
(CDAI – 275). 
Female - episode of major 
depression, superimposed 
on a chronic mild 
depressed state 
(dysthymia). As 
diagnosed by a clinician.  
 
Female - 
At least 
19 
months  
 
Male – 
NR 
Scott (1999), 
USA 
Case Report 42-year old black male. 
Prescribed 6-
metacaptopurine, 
prednisolone and total 
parenteral nutrition.  
 
80mg/day amitriptyline administered 
intramuscularly – discontinued after 19 days 
due to pain at injection site. 
 
Afterwards 150mg amitriptyline gel was 
applied to patient’s chest at bedtime. 
CD Severe flare up of 
CD, pain 8/10 on 
visual analogue 
scale despite 
morphine. 
Sertraline previously 
prescribed for major 
depression, 
unsuccessfully. 
Amitriptyline was 
successful. 
6 weeks 
Joshni (2013), 
India  
 
Case Report 
(Abstract) 
26-year old male. 
Previously received 
immunomodulators and 
courses of steroids without 
relief. 
Patient received mirtazapine (15mg) at night. UC NR Generalised anxiety 
disorder, as diagnosed by 
a clinician.  
 
6 weeks 
Kahn (2004), 
USA 
 
Case Report 
(Abstract) 
64 year-old male. 
 
Medications included 
adalimumab, aripiprazole, 
mirtazapine, and sertraline. 
Patient received the ADs mirtazepine and 
sertraline. 
CD 6 months of 
chronic, watery, 
non-bloody 
diarrhoea. 4-6 
watery bowel 
movements per day. 
Severe depression, as 
diagnosed by a clinician.  
 
NR 
Table 6: Summary of the primary and secondary outcomes in the included studies  
Author (Year), 
Country 
Study Design Primary Outcome - IBD  Secondary Outcome - Anxiety & Depression Conclusions 
Daghaghzadeh 
(2015), Iran 
Placebo-
controlled 
RCT 
Severity of symptoms significantly improved compared to control 
(p=0.02). Intervention: mean (SE) 6.23 (1.00) to 4.52 (0.54); Control: 
mean (SE) 7.50 (0.80) to 6.83 (0.69). 
 
 
Depression significantly improved compared 
to control (p=0.041). Intervention: mean (SE) 
8.64 (0.89) to 7.47 (0.80); Control: mean (SE) 
9.77 (0.75) to 10.50 (1.18). 
 
Anxiety significantly improved compared to 
control (p=0.049). Intervention: mean (SE) 
7.94 (1.03) to 6.11 (0.99); Control: mean (SE) 
8.38 (1.04) to 8.50 (1.14). 
Duloxetine recommended 
for disease activity, 
anxiety and depression. 
Yanartas (2016), 
New Zealand 
Prospective 
Cohort 
AD treatment was found to be associated with an improvement in 
CDAI in patients with IBD.  Intervention: 197.41 (130.60) to 101.08 
(65.88) (p=0.011); Control: 58.50 (74.94) to 83.50 (62.68) (p=0.710). 
No significant difference was observed between groups (p=0.570). 
 
MMS - Intervention: 2.71 (3.05) to 0.94 (1.91) (p=0.054); Control: 
2.78 (3.42) to 1.77 (1.98) (p=0.464). No significant difference was 
observed between groups (p=0.926). 
 
CRP decreased insignificantly in both groups. Intervention: 6.58±13.89 
to 4.61±4.03 (P=0.324); Control: 4.30±3.79 to 4.35±3.47 (P = 0.949).  
No significant difference was observed between groups (P =0.656). 
Depression (HAD-D) improved. Intervention: 
10.62 (3.61) to 3.35 (4.01); Control: 11.55 
(2.85) to 10.15 (3.51). 
 
Anxiety (HAD-A) improved.  Intervention: 
12.38 (4.38) to 5.97 (4.45); Control: 11.40 
(4.60) to 11.05 (4.40). 
 
ADs recommended for 
disease activity, anxiety 
and depression. 
Iskandar (2014), 
USA 
Retrospective 
Cohort 
Likert baseline severity scores (CD: 2.07 ± 0.03, UC: 2.03 ± 0.04, P = 
0.67). UC patients responded significantly better to TCA therapy, 1.86 
± 0.13 for UC and 1.26 ± 0.11 for CD (P = 0.003). 83% of UC patients 
had at least a moderate symptomatic improvement on TCA, compared 
with 50% of CD patients (P = 0.01).  
 
No significant difference at the second follow-up visit. Mean response 
score of 1.31 ± 0.16 for CD and 1.47 ± 0.17 for UC, P = 0.76. At the 
second visit, 56% of CD group and 40% of UC group had at least a 
further moderate symptom response, P = 0.16. 
Not measured Low-dose TCAs 
recommended for 
management of residual 
symptoms in IBD patients 
with minimal 
inflammation. 
Goodhand (2012), 
USA 
Retrospective 
Case-control  
Fewer relapses and courses of steroids in the year after starting an AD 
than in the year before (1 [0–4] (median [range]) vs. 0 [0–4], P=0.002; 
1 [0–3] vs. 0 [0–4], P < 0.001, respectively); the controls showed no 
changes between years 1 and 2 in relapses (1 [0–4] vs. 1 [0–3], 
respectively) or courses of steroids (1 [0–2] vs. 0 [0–3]). 
Not measured ADs recommended for 
disease activity. 
 
Mikocka-Walus 
(2014), Australia 
Cross-
Sectional 
Survey 
Respondents reported taking an AD for an average of four (SD = 3.9) 
years ranging from four weeks to 15 years. 
 
Psychological well-being had improved in 
87% (n = 55) of participants. 
 
ADs recommended for 
anxiety and depression.  
79% reported perceived improvements despite 67% observing no 
change in disease activity. Disease activity improved in 25% of 
participants.  
Mikocka-Walus 
(2012b), Australia 
Qualitative - 
Interview 
ADs improved QoL – primarily psychological, as well as social and 
biological. 
 
5 (33%) – helped disease course 
3 (20%) – reduction in pain and frequency of bowel movements 
10 (66%) – didn’t influence disease course, but difficult to distinguish 
between treatments 
3 (20%) – reduction in frequency of symptoms or flare ups 
Three (20%) patients noted how they 
believed the reduction in feelings of stress 
mediated the positive influence of the AD on 
IBD course. 
 
ADs recommended for 
anxiety and depression. 
Mikocka-Walus 
(2012a), Australia 
Report on 
Clinical Case-
Note Audit 
51 currently taking ADs. 71 received ADs in the past. 
 
Disease activity on ADs (n=51):  
15 (29%) - inactive disease but presented with symptoms such as pain 
or diarrhoea, consistent with functional bowel disorders. 
11 (22%) - full remission with no disease activity 
2 (0.04%)- active disease 
23 (45%) - no data were recorded 
Of the 51 patients currents taking ADs, 45% 
were taking them for depression or combined 
anxiety and depression disorder (23%).   
ADs recommended for 
disease activity. 
Ramos Rivers 
(2014), USA 
Audit 
(Abstract) 
There was a difference in proportion of poorer SIBDQ (OR=22.88, 
95% CI=8.89-58.89,  P < 0.0001) and higher IBD activity (OR=6.34, 
95% CI=2.91-13.80,  P < 0.0001) in those taking SSRIs vs. those who 
did not but not in proportion with CRP in those taking SSRIs (OR=1. 
78, 95% CI= 0.92-3.42, P = 0.09).  Mean IBD activity decreases over 
time, independent of SSRI use.  
Not measured ADs are not 
recommended for disease 
activity.  
Walker (1996), 
USA 
Case-series Not measured Mean (SD) HAM-D improvement (pre-
treatment 29.0±7.7; post-treatment 8.1±6.1, 
p=0.0001). 
ADs recommended for 
anxiety and depression. 
Kane (2003), USA Case Report Decrease in CDAI to <150 within 6 weeks (without other changes to 
IBD medication). 
Not measured Bupropion recommended 
for disease activity. 
Kast (1998), USA Case report First 7-days bowel movements described as soft, 3-4 per day with 
cramping. After increase to 30mg, one bowel movement per day with 
no cramping. Other medication tapered off. After 2 years phenelzine 
stopped, 6 weeks later admitted to hospital with CD relapse. 
Depression responded well. Phenelzine recommended 
for disease activity and 
depression. 
Kast (2001), USA Case Report Female: 19-month remission, any attempts to stop bupropion were 
associated with relapse. CDAI = 0. Mesalamine was tapered off. 
 
Male: CDAI=45. 3-4 episodes of diarrhoea daily due to ileal-cecal 
value. 
Female - major depression remitted. The 
baseline dysthymia remained. 
Bupropion recommended 
for disease activity and 
depression. 
Scott (1999), USA Case Report Patient’s abdominal pain remained unchanged, assessed by visual 
analog scale, but no adverse events were associated with transdermal 
amitriptyline. 
Psychiatrist determined patient’s depression 
had not responded adequately.  Although man 
Amitriptyline no effect on 
IBD.  
RCT – Randomised controlled trial; SE – Standard error; SD – Standard deviation; AD – Antidepressants; MMS – Modified Mayo Score; CDAI – Crohn’s disease activity index; IBD – 
Inflammatory bowel disease; CRP – C-reactive protein; HAD-A – Hospital anxiety and depression scale -A; HAD-B - Hospital anxiety and depression scale -A; UC – Ulcerative colitis; CD – 
Crohn’s disease; TCA – Tricyclic antidepressants; QoL – Quality of Life; CI – Confidence interval; SSRI – Selective Serotonin reuptake inhibitor.  
 
stated his mood had improved at the end of 6-
week therapy. 
Joshni (2013), India Case Study 
(Abstract) 
After 2 weeks decreased urgency of defecation and reduced tenesmus 
were reported. After 6 weeks, there was complete resolution of bloody 
diarrhoea and rectal pain. 
Improvement in anxiety features in 2 weeks. 
After 6 weeks patient had relief from anxiety 
features. 
Mirtazapine 
recommended for disease 
activity and anxiety. 
Kahn (2004), USA 
 
Case Study 
(Abstract) 
Treatment ineffective. Became effective when psychiatrist changed 
sertraline to bedtime dosing. 
Not measured Night dosing of 
mirtazapine and sertraline 
recommended for disease 
activity. 
